GlassScriptPhysician profile
Jose Sarriera
NPI 1255315933
$31,943.73
in general payments reported to CMS, 2019-2025
20 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,836 · 2020: $3,284 · 2021: $2,229 · 2022: $1,735 · 2023: $12K · 2024: $8,029 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $1,730 · Food and Beverage: $247 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,657.50 |
| Travel and Lodging | $1,729.63 |
| Food and Beverage | $247.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $9,755.94 | 2023 | Adcetris |
| Alexion Pharmaceuticals, INC. | $7,913.67 | 2019-2024 | |
| Beigene USA, INC. | $3,900.00 | 2022-2023 | Brukinsa |
| Kite Pharma, INC. | $3,040.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $2,200.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $1,921.59 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,100.00 | 2019 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Beigene, LTD. | $525.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $300.00 | 2024-2025 | Talvey |
| Novartis Pharmaceuticals Corporation | $225.00 | 2024 | |
| Pfizer INC. | $150.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Genentech USA, INC. | $111.15 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Sarriera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.